Acorda Therapeutics, Inc.
ACOR · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -46.6% | 37.1% | -6.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.7% | 65% | 87.8% | 89.7% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -62.4% | -607.5% | 1.3% | 10.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -135% | -573.3% | -32.1% | -31.6% |
| EPS Diluted | -22.06 | -225.81 | -7.16 | -7.55 |
| % Growth | 90.2% | -3,053.8% | 5.2% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |